Cargando…

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

BACKGROUND: Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil (5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11. Therefore, we designed a sequential combination, in which CPT-11 infusion was given on day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshioka, T, Kato, S, Gamoh, M, Chiba, N, Suzuki, T, Sakayori, N, Shibata, H, Shimodaira, H, Otsuka, K, Kakudo, Y, Takahashi, S, Ishioka, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795445/ https://www.ncbi.nlm.nih.gov/pubmed/19920821 http://dx.doi.org/10.1038/sj.bjc.6605432

Ejemplares similares

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
por: Yamada, Y, et al.
Publicado: (2018)

Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion
por: Shiono, Masatoshi, et al.
Publicado: (2014)

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
por: Komatsu, Yoshito, et al.
Publicado: (2015)

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
por: IMAI, HIROO, et al.
Publicado: (2014)

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers
por: Takahashi, Masanobu, et al.
Publicado: (2021)

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
por: Li, Wenhua, et al.
Publicado: (2014)

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
por: Delord, J-P, et al.
Publicado: (2007)

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
por: Jeung, H-C, et al.
Publicado: (2006)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
por: Tate, Shinichi, et al.
Publicado: (2020)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
por: Imai, Hiroo, et al.
Publicado: (2020)

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
por: Carlsson, G., et al.
Publicado: (2022)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
por: Schoemaker, N E, et al.
Publicado: (2004)

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial
por: Köhne, C-H, et al.
Publicado: (2003)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

Overexpression of DRAM enhances p53-dependent apoptosis
por: Takahashi, Masahiro, et al.
Publicado: (2013)

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer
por: Ouchi, Kota, et al.
Publicado: (2015)

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
por: Vasile, E, et al.
Publicado: (2009)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
por: Bazarbashi, Shouki, et al.
Publicado: (2015)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
por: Cheng, Ke, et al.
Publicado: (2022)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201
por: Takahashi, Shin, et al.
Publicado: (2023)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
por: Kim, S Y, et al.
Publicado: (2013)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer
por: Trumpi, K., et al.
Publicado: (2015)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
por: Burtness, Barbara, et al.
Publicado: (2016)

Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer
por: Ogata, Yutaka, et al.
Publicado: (2013)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k64hb5o733i5ukasjkngibd4pn